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Abstract
The number of neuroimaging studies has grown exponentially in recent years and their results are not always
consistent. Meta-analyses are helpful to summarize this vast literature and also offer insights that are not apparent
from the individual studies. In this review, we describe the main methods used for meta-analyzing neuroimaging
data, with special emphasis on their relative advantages and disadvantages. We describe and discuss meta-
analytical methods for global brain volumes, methods based on regions of interest, label-based reviews, voxel-
based meta-analytic methods and online databases. Regions of interest-based methods allow for optimal statistical
analyses but are affected by a limited and potentially biased inclusion of brain regions, whilst voxel-based methods
benefit from a more exhaustive and unbiased inclusion of studies but are statistically more limited. There are also
relevant differences between the different available voxel-based meta-analytic methods, and the field is rapidly
evolving to develop more accurate and robust methods. We suggest that in any meta-analysis of neuroimaging
data, authors should aim to: only include studies exploring the whole brain; ensure that the same threshold
throughout the whole brain is used within each included study; and explore the robustness of the findings via
complementary analyses to minimize the risk of false positives.
Keywords: activation likelihood estimation, effect-size signed differential mapping, functional magnetic resonance
imaging, kernel density analysis, meta-analysis, magnetic resonance imaging, multilevel kernel density analysis, para-
metric voxel-based meta-analysis, region of interest, signed differential mapping, voxel-based morphometry
Introduction
The number of neuroimaging studies has grown exponen-
tially in recent years. However, findings from different stu-
dies may sometimes be difficult to integrate into a
coherent picture. Inconsistent results are not uncommon.
Furthermore, a few influential studies might often eclipse
robust findings from other studies. In other words, we
may at times not see the forest for the trees. In this con-
text, meta-analyses are helpful to combine and summarize
the data of interest and potentially offer insights that are
not immediately apparent from the individual studies.
The present paper aims to describe the main methods
which have been used for the meta-analysis of neuroima-
ging data, as well as their advantages and drawbacks,
with some examples of application to mood and anxiety
disorders. The first section of the paper introduces how a
standard meta-analysis is conducted, that is, when there
is only one variable of interest, with an example from a
meta-analysis of global brain volumes. This is important
for a better appreciation of the pros and cons of the
meta-analytic methods that we review later. The second
section of the paper describes the meta-analyses of neu-
roimaging studies based on regions of interest (ROI) and
their particular issues. The third section introduces the
various available voxel-based meta-analytic methods,
which aim to overcome some of the limitations of the
ROI-based methods but have, in turn, their own limita-
tions. The similarities and differences between the var-
ious voxel-based methods are also discussed in depth.
Finally, we describe the available online databases of neu-
roimaging studies. This paper is meant to be accessible
for the applied researcher in the fields of psychiatry, neu-
rology and allied disciplines. Other excellent, more tech-
nical, reviews of meta-analytical methods can be found
elsewhere [1,2]. * Correspondence: Joaquim.Radua@kcl.ac.uk
1Institute of Psychiatry, King’s College London, De Crespigny Park, London,
UK
Full list of author information is available at the end of the article
Radua and Mataix-Cols Biology of Mood & Anxiety Disorders 2012, 2:6
http://www.biolmoodanxietydisord.com/content/2/1/6 Biology of 
Mood & Anxiety Disorders
© 2012 Radua and Mataix-Cols; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Standard meta-analyses
Prior to any meta-analytic calculation, researchers con-
duct an exhaustive and critical literature search, often
including contact with the authors of the original studies
in order to retrieve important pieces of missing informa-
tion. Then, researchers conduct a mathematical summary
of the findings of the included studies (that is, the meta-
analysis proper). Finally, researchers apply a series of
tests, plots and subgroup analyses to assess the heteroge-
neity and robustness of the results. The latter step, along
with the exhaustive and critical inclusion of studies, is of
utmost importance in order to obtain unbiased meta-
analytic conclusions.
With the aim of introducing the reader to the logics of
a standard meta-analysis, in this section we will use as an
example a meta-analysis of global gray matter volumes in
patients with obsessive-compulsive disorder (OCD) (see
Table 1). The included studies correspond to seven publi-
cations reporting global gray matter volume, which were
included in a published meta-analysis of voxel-based
morphometry studies in OCD [3].
Weighting of the studies
In order to summarize these seven studies, a simple
meta-analysis could consist of calculating the mean dif-
ference in global gray matter volume between patients
and controls as reported in the original studies [4]. Thus,
we could summarize Table 1 by saying that the mean glo-
bal gray matter volume is 8.4 mL inferior in patients than
in healthy controls-this number is just the arithmetic
mean of the differences shown in the table.
T h eu s eo ft h ea r i t h m e t i cm e a n ,h o w e v e r ,m a yb et o o
simplistic, because the different studies should have dif-
ferent weights. For example, the number of patients in
study 4 is four times larger than the number of patients
in study 1. Clearly, we cannot give the same weight to
both studies and should give more weight to study 4.
Probably, we should give it about four times more weight,
as it includes four times as many patients.
Including all the studies in Table 1 and weighting the
mean difference by the sample sizes of the studies, we
would conclude now that the mean global gray matter
volume is 8.8 mL inferior in patients than in controls.
Note that when we previously calculated the mean dif-
ference as the simple arithmetic mean, we were indeed
assuming that all the studies had the same sample size.
This erroneous assumption had only a minor effect here
(we thought that the difference was about 5% smaller
than what we think now), but it could have important
effects in other meta-analyses, especially if studies with
smaller sample sizes inexplicably find more differences
than studies with larger sample sizes-we will introduce
how to detect this kind of bias later.
Unfortunately, weighting the calculations only by sam-
p l es i z ew o u l ds t i l lb et o os i m p l i s t i c ,b e c a u s et h ew e i g h t
of a study should also include its precision. For example,
study 1 included fewer patients than study 4, but its
volume estimates seem much more precise, as its sample
variance is approximately the half than that in study 4
(see Patients + controls column in Table 1). We do not
know the reason for this higher precision (maybe the
sample was more homogenous; maybe the technical pro-
cedures were cleaner; maybe it was just chance); however,
we must take this precision into account by weighting by
the inverse of the variance of the difference-which also
includes the sample size.
Including all the studies in Table 1 and weighting by
t h ei n v e r s eo ft h ev a r i a n c eo ft h ed i f f e r e n c e ,w ew o u l d
conclude that the mean global gray matter volume is 8.9
mL inferior in patients than in controls (z-value = -1.55,
P = 0.121). When previously we did not weight by sample
variance we were assuming that all the studies had the
same variance, though in this case this assumption was
acceptable because the variance of the studies is rather
homogeneous.
However, as explained in the next section, weighting
the calculations only by the inverse of the variance of
the difference may still be too simplistic.
Heterogeneity in the studies
Healthy individuals have different global gray matter
volumes, that is, some have larger brains, some have
thicker cortices, and so on. When conducting an analysis
with original data, we are usually able to explain or
Table 1 Global gray matter volumes reported in seven studies on obsessive-compulsive disorder
Reference Patients Controls Patients + controls Difference Effect size
Number Volume ± SD Number Volume ± SD N Variance Estimate Variance Estimate Variance
Study 1 [46] 18 773 ± 56 18 822 ± 56 36 3,114 -49 346 -0.854 0.122
Study 2 [47] 55 685 ± 74 50 708 ± 72 105 5,323 -23 203 -0.313 0.039
Study 3 [48] 25 850 ± 83 25 834 ± 71 50 5,997 +16 480 0.196 0.080
Study 4 [49] 72 739 ± 82 72 763 ± 78 144 6,404 -24 178 -0.298 0.028
Study 5 [50] 37 776 ± 69 26 747 ± 68 63 4,680 +29 307 0.418 0.067
Study 6 [51] 19 827 ± 44 15 836 ± 63 34 3,041 -9 363 -0.179 0.120
Study 7 [52] 71 740 ± 66 71 738 ± 63 142 4,119 +2 116 0.035 0.028
All volumes are in milliliters. SD: standard deviation.
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this variability that remains unexplained. This residual
error may be due to unobserved variables, etiological het-
erogeneity within particular diagnoses, poor model fit-
ting, or maybe just pure chance. This individual-based
within-study variability cause the sample means to be
variable, so that different studies obtain different results.
However, within-study variability is not the only source
of the between-study variability or heterogeneity. Given
the relatively small amount of robust findings in neuroi-
maging, it would be highly desirable that all researchers
conducted their studies using the exact same inclusion
criteria and methods so that all between-study variability
was only related to the within-study variability. However,
the fact is that clinical and methodological differences
between studies are often substantial.
On the one hand, patients included in the individual stu-
dies may have been sampled from clinically different
populations; for example, one study of major depressive
disorder may include outpatients with mild reactive
depressive episodes while another study may be focused
on inpatients suffering from severe endogenous depres-
sions with melancholic symptoms. Similarly, patients in
different studies may be receiving different treatments, or
be in different phases of the disorder (for example, having
a first episode or having a history of multiple episodes).
On the other hand, researchers may have been investi-
gated similar but still different aspects of a disorder; for
example, one study may have described the blood oxygen
level-dependent (BOLD) brain response to a task involving
a high memory load, while another study may be interest
in the BOLD response to a task related to decision-making.
Or even if studying the same particular cognitive function,
each study may employ a particular statistical package, and
its large set of associated assumptions.
Finally, there may be a relevant part of the between-
study heterogeneity which can be neither related to the
within-study variability, nor explained by clinical or
methodological differences between studies. This is called
residual heterogeneity.
It is highly recommended to study the between-study
variability or heterogeneity in any meta-analysis. For
example, if the main analysis detects differences between
patients and controls, it may be of interest to explore
whether these differences depend on the severity of the
disorder, or if they are related to special subtypes of the
disorder. These questions may be assessed with meta-
regressions. But even if the meta-analysis does not aim to
explore the modulating effects of clinical variables on the
main outcomes, heterogeneity should still be taken into
account.
Indeed, there is agreement on always including the
residual heterogeneity in the weighting of the calculations
[5-8]. Meta-analyses conducted this way are said to
follow random-effects models, in opposition to the fixed-
effects models that we saw in the previous point, which
did not include heterogeneity. In the example of Table 1
the use of a random-effects model would lead us to con-
clude that the mean global gray matter volume is 9.0 mL
inferior in patients than in controls (z-value = -0.98, P =
0.328; see Figure 1, left). Note the increase of P-value in
the random-effects model (from 0.121 to 0.328), thus bet-
ter controlling the false positive rate.
Other complementary analyses
The above meta-analysis of global gray matter volumes in
OCD was only aimed to help interpret the findings of a
regional voxel-based meta-analysis, for which no other
tests beyond a correctly weighted random-effects model
would probably be required. However, if global gray mat-
ter volumes were the main outcome of a meta-analysis,
some complementary plots and tests would be recom-
mended to help the reader assess the reliability and
robustness of the findings [9].
On the one hand, the meta-regressions described above
may be useful for assessing if the findings are predomi-
nantly (or only) present in one group of patients, for
example, in those with more severe forms of OCD. In
this regard, specific meta-analyses of subgroups of
patients may further confirm these hypotheses or, also
important, may state that the abnormalities are present
in all subgroups of patients, increasing the robustness of
the findings. Similarly, sensitivity analyses consisting of
repeating the meta-analysis many times, each time with a
different combination of studies, may be useful to assess
w h e t h e rt h ef i n d i n g sa r ed r i v e nb yo n eo rf e ws t u d i e s .
Finally, funnel plots (see Figure 1, right) may be useful
for appraising whether studies with small samples report
more statistically significant findings than studies with
larger samples. This is typical of subjects with publication
bias, where studies with small samples are only published
if their results match a priori hypotheses.
It is important to note that these kinds of tests and gra-
phical aids are necessary but do not provide conclusive
information, and should only be interpreted in the context
of the field under investigation. A symmetrical funnel plot,
for example, is not an amulet against publication bias,
especially in some types of meta-analysis. ROI-based stu-
dies, for instance, may be more prone to be affected by
publication biases, as the authors may decide which brain
regions are reported and which are not. Conversely, an
asymmetrical funnel plot would not necessarily invalidate
a meta-analysis if publication bias appears unlikely. This
may be the case of voxel-based studies, where the whole
brain is included in the analysis.
Use of effect sizes
Most meta-analyses do not use the raw volume differ-
ences as we exemplified in the previous points, but
rather, they use standardized volume differences, that is,
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in milliliters between patients’ and controls’ global gray
matter volume, while a standardized difference is the
difference is standard deviations-usually corrected for
small sample size bias.
This subtle difference has a series of consequences. First,
the unit of measure (milliliters, in this case) is lost, which
makes the interpretation of the findings less straightfor-
ward but indeed more comparable with other measures,
for example, an effect size of d = 0.5 is considered ‘med-
ium’ independently of whether it refers to a difference in
gray matter volume, in BOLD response or in a question-
naire score. Using the data from Table 1, the effect size of
t h ed i f f e r e n c ei ng l o b a lg r a ym a t t e rv o l u m eb e t w e e n
patients and controls is d = -0.122 (z-value = -0.93, P =
0.354; Figure 2), which is below the conventional range of
‘small’ effect (0.2 to 0.3) [11]. Second, a study reporting a
larger difference may be found to have a smaller effect
size, or vice versa, depending on the sample variance. For
instance in Table 1, the raw difference is slightly larger in
study 4 than in study 3, whilst the effect size is slightly lar-
ger in study 3 than in study 4. Third, and very important,
effect size can be directly derived from many statistics like
a t-value or a P-value, which are much more often
reported than sample statistics; that is, we can often know
the effect size but not the raw difference. This advantage
u s u a l l ya l l o w sam u c hm o r ee x h a u s t i v ei n c l u s i o no fs t u -
dies, thus clearly justifying the use of effect sizes in many
meta-analyses.
Meta-analyses based on regions of interest
A ROI is a part of the brain that the authors of the
study wish to investigate, usually based on ap r i o r i
hypotheses. ROI-based studies usually select a set of few
ROIs and manually delimitate them on the raw images.
Researchers then analyze the volume of these ROIs,
their mean BOLD response to a stimulus, their positron
emission tomography ligand volume of distribution, or
any other measure of interest.
Region of interest-based meta-analyses
A typical ROI-based meta-analysis can be viewed as a set
of different meta-analyses, each of them applied to a dif-
ferent ROI. These meta-analyses can usually be optimally
conducted with all appropriate weightings and comple-
mentary analyses, as seen for example in the meta-analy-
sis of regional brain volumes in OCD conducted by
Rotge et al. [12], in which the analyses are based on effect
sizes and random-effects models and complemented with
explicit assessments of the heterogeneity, several sensitiv-
ity analyses, funnel plots and meta-regressions. Unfortu-
nately, each original study included in this meta-analysis
only investigated a small set of brain regions, causing the
meta-analyses to include only a very small number of stu-
dies for each brain region. Indeed, only three or four stu-
dies could be included for highly relevant regions such as
the putamen or the anterior cingulate cortex, both of
which were found as abnormal in subsequent voxel-
based meta-analyses [3,13]. Other brain regions could
not be meta-analyzed because they had been investigated
by too few or no studies. Needless to say, this would not
be the case for those ROI studies reporting whole brain
results in online supplements or similar, but this is sel-
dom the case.
Moreover, it must be noted that some brain regions
are more frequently studied than others, which causes
the statistical power to differ depending on the brain
Figure 1 Forest (left) and funnel (right) plots of the mean differences in global gray matter volume between patients with obsessive-
compulsive disorder and healthy controls (using a random-effects model). On the funnel plot, the included studies appear to be
symmetrically distributed on either side of the mean difference, suggesting no publication bias towards positive or negative studies.
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studies or more were available for the orbitofrontal cor-
tex, the thalamus and the caudate nuclei, some brain
regions could not be meta-analyzed at all.
Ultimately, the authors of the original studies have a set
of ap r i o r ihypotheses which influence their decision to
investigate differences in a given brain region at the
expense of other regions. These decisions determine the
number of studies investigating that brain region, and
thus the statistical power to detect that brain region as
significantly different between patients and controls in a
ROI-based meta-analysis. Publication bias is also a pro-
blem as studies failing to report statistically significant
differences on hypothesized ROIs may be less likely to
ever be become publicly available. A recent analysis of
more than 450 ROI-based neuroimaging studies in psy-
chiatry illustrates this point well [14]. The author demon-
strated that the number of studies reporting significant
results was nearly the double than expected, suggesting
strong publication biases in the ROI literature.
Another consideration is the heterogeneous definition or
the boundaries of the ROIs, which may differ from one
s t u d yt ot h eo t h e r[ 1 2 ] .H o w e v e r ,t h i sv a r i a b i l i t ym i g h t
have a relatively small impact on effect sizes, as boundary
definitions are the same for the patients and controls
included in a study. Furthermore, the spatial error may
probably be counteracted by the higher anatomical accu-
racy achieved by the manual delimitation of the ROIs in
the original studies [15,16].
Label-based reviews
Some authors have used a simplified type of ROI-based
meta-analysis, consisting of just counting how many times
a particular ROI is detected as significantly abnormal in
patients versus healthy controls. This procedure has been
called label-based review [17]. For example, in their func-
tional neuroimaging meta-analysis of the brain’s response
to emotional tasks, Phan et al. [18] represented each acti-
vation peak as a dot in an atlas of the brain. They then
divided the brain into 20 ROIs and counted how many
studies had one or more activation peak in each ROI.
A fictitious example of such approach is shown in
Figure 3A. Here, the studies would have reported that
the patients with mood or anxiety disorders have
increases of gray matter volume in the basal ganglia,
extending to the anterior part of the right insula, as well
as decreases of gray matter volume in the anterior cin-
gulate and insular cortices. The authors of a label-based
review would have first plotted the peaks of the clusters
of significant increase (red) or decrease (blue) of gray
matter volume in a brain template. Then, they would
divide the brain into several regions, for example, ante-
rior cingulate gyrus, left and right inferior frontal gyri,
insulas, superior temporal gyri, caudate nuclei, putamen
nuclei, and so on. Finally, they would have counted how
many peaks lay within each of these regions.
This method may be useful when other approaches are
not feasible, for example when not enough information is
available for conducting a ROI-based or a voxel-based
meta-analysis. Its simplicity, however, may conceal a ser-
ies of important drawbacks which must be taken into
account. First, no weighting of the studies is performed,
which means that all studies are assumed to have the
same sample size and precision. This is a strong and
unrealistic assumption which may be violated in most
meta-analysis. Fortunately, sample size information is
always available, and so label-based meta-analyses should
Figure 2 Forest (left) and funnel (right) plots of the effect size of the differences in global gray matter volume between patients with
obsessive-compulsive disorder and healthy controls (using a random-effects model). On the funnel plot, the included studies appear to
be symmetrically distributed on either side of the mean effect size, suggesting no publication bias towards positive or negative studies.
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of the studies are binarized (significant versus not-signifi-
cant), leading to a loss of information on the magnitude
of the raw differences or on the effect sizes. Third, it is
not clear whether studies reporting opposite findings in a
particular ROI (for example, volume decrease in some
studies and volume increase in others) are adequately
dealt with. Finally, they may be also affected by the parti-
cular issues of ROI-based meta-analyses described above.
Voxel-based meta-analyses
Scanner three-dimensional images are composed of
thousands of tiny cubes (or rectangular cuboids) called
voxels, in the same way that digital photographs are
composed of thousands of tiny squares called pixels.
Voxel-based methods consist of conducting the meta-
analytic calculations separately in each voxel of the
brain, thus freeing the meta-analysis from aprioristic
anatomical definitions. There are different types of
voxel-based meta-analyses, including image-based, coor-
dinate-based and mixed image- and coordinate-based
meta-analyses.
Image-based meta-analyses
An image-based meta-analysis should be understood as a
voxel-based version of the standard meta-analysis, that is,
it consists of thousands of standard meta-analyses, each
of them applied to a different voxel [2,19]. The data of
each study is retrieved from its statistical parametric
maps (the three-dimensional images resulting from the
comparison between patients and controls), and thus
include the whole brain. This technique shares some lim-
itations with any voxel-based analysis, mainly relating to
the massive number of statistical tests (that is, one test
for each voxel). The correction of multiple comparisons
is an unsolved issue, with current methods being either
too liberal or too conservative [19]. For this reason,
thresholds based on uncorrected P-values and cluster-
size are usually preferred [1,19,20]. Also, such massive-
scale testing prevents a careful visual inspection of the
analyses (for example, to describe relevant non-signifi-
cant trends).
However, the biggest drawback of image-based meta-
analyses is that the statistical parametric maps of the
original studies are seldom available, therefore seriously
limiting the inclusion of studies.
Coordinate-based meta-analyses
Given the poor availability of statistical parametric
maps, early meta-analyses of voxel-based studies con-
sisted of label-based (rather than image-based) reviews,
as discussed earlier. These methods quickly evolved to
coordinate-based meta-analyses, which in their simplest
form consisted of counting, for each voxel, how many
activation peaks had been reported within its surround-
ings [21]. In the fictitious example, the dots of the label-
based review (Figure 3A) would be replaced with
spheres (Figure 3B, C), and the brain would not be
Figure 3 Summary of the main available voxel-based meta-analytic methods. Increases and decreases of gray matter volume are fictitious
and have been manually plotted over a MRICroN template to illustrate the main features of the different methods.
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of spheres surrounding each voxel would be counted,
thus obtaining a count for each voxel. It must be noted
that calculations in activation likelihood estimation
(ALE) [22] are not exactly based on counting the num-
ber of spheres but on computing the probability of a
union, though in practice, the latter behaves like the
former.
The use of voxels rather than conventional divisions of
the brain improved the anatomical localization of the
f i n d i n g s .H o w e v e r ,t h ef i r s ta v a i l a b l em e t h o d s ,n a m e l y
ALE and kernel density analysis (KDA) [21], had some
additional issues which enlarged the list of drawbacks of
label-based reviews. Specifically, they only counted the
total number of peaks, independently of whether they
c a m ef r o mt h es a m eo rd i f f e r e n ts t u d i e s ,a n dt h u st h e
analysis could not be weighted by sample size and a sin-
gle study reporting many peaks in close proximity could
drive the findings of the whole analysis.
These drawbacks led to the creation of a second gen-
eration of coordinate-based meta-analytic methods,
mainly evolved versions of KDA, such as multilevel KDA
[23] and parametric voxel-based meta-analysis [24];
evolved versions of ALE [25,26]; and signed differential
mapping (SDM) [3,27-30] (Figure 3D, E), which over-
came these limitations by separating the peaks of each
study. Moreover, some of these new methods weighted
the studies by their sample size and included a series of
complementary analyses to assess the reliability and
robustness of the findings. One of the methods, SDM,
also addressed between-study heterogeneity by recon-
structing positive and negative maps in the same image,
thus counteracting the effects of studies reporting find-
ings in opposite directions [31] and incorporating meta-
regression methods. Finally, SDM included templates for
white matter [32], allowing multimodal meta-analyses
which were not possible with previous methods [33].
However, these methods still did not employ the stan-
dard statistical methods of the ROI-based meta-analyses,
for example, they did not weight by the precision of each
study.
Several of these methods have recently been applied to
mood and anxiety disorders. One such was a meta-ana-
lysis of studies investigating bipolar disorder [34] using
SDM, which found patients to have gray matter reduc-
tions in the left medial frontal and/or anterior cingulate
cortex (MF/ACC) and bilateral anterior insula, with
complementary analyses showing findings in the left
A C Ca n dr i g h ti n s u l at ob er o b u s t ,a n dl e f tM F / A C C
volume to be higher in samples where patients were
being treated with lithium. An SDM meta-analysis of
studies investigating major depressive disorder also
found patients to have gray matter reductions in the
MF/ACC [35], and complementary analyses showed this
finding to be robust and more severe in multiple-epi-
sode samples. Recent SDM meta-analyses of studies
investigating anxiety disorders have also found patients
to have gray matter reduction in the MF/ACC [13],
along with abnormalities in the basal ganglia. Specifi-
cally, patients with OCD were found to have increased
gray matter volume in the bilateral putamen and cau-
date nuclei [3], with complementary analyses showing
findings in the MF/ACC and left basal ganglia to be
robust, and bilateral increases of basal ganglia volume to
be higher in samples including patients with higher
symptom severity. Conversely, patients with anxiety dis-
orders other than OCD were found to have decreased
gray matter volume in the left putamen nucleus [13].
An example of the use of these methods in functional
neuroimaging is the recent study by Delvecchio et al.
[36], which meta-analyzed the functional brain response
to emotional faces using ALE. They found that both
patients with bipolar disorder and patients with unipolar
depression displayed limbic hyperactivations. However,
only patients with bipolar disorder showed a set of
hypoactivations in the prefrontal cortex and hyperactiva-
tions in the thalamus and basal ganglia. Conversely, only
patients with major depressive disorder showed hypoac-
tivations in the sensorimotor cortices. Another example
from the anxiety disorders literature is a multilevel KDA
meta-analysis, which found that patients showed hyper-
activations in the amygdala and insula [37]. Interest-
ingly, these hyperactivations were more observed in
phobias, whilst patients with post-traumatic stress disor-
der displayed a hypoactivation of the MF/ACC. Finally,
an ALE meta-analysis of functional differences in
patients with OCD detected that symptom provocation
was possibly associated with activation of the orbitofron-
tal cortex, prefrontal cortex, anterior cingulate cortex,
precuneus, premotor cortex, superior temporal gyrus,
basal ganglia, hippocampus and uncus [38].
These methods may also be applied to functional con-
nectivity studies [39,40]. Laird et al., for instance, studied
the default mode network by first creating ALE maps,
and then deriving meta-analytic co-activation maps [40].
With this approach, they could identify an affective sub-
network component. This approach is promising, given
the increasing interest in functional connectivity studies
in various mood and anxiety disorders.
Mixed image- and coordinate-based meta-analyses
Recently, effect size SDM (ES-SDM) was designed to
allow the combination of studies from which images (sta-
tistical parametric maps) are available with studies from
which only peak coordinates are reported, thus allowing
a more exhaustive inclusion of studies, as well as more
accurate estimations [19].
This is achieved by first using peak coordinates and
their statistical values to recreate the statistical
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meta-analysis. Thus, this method has some statistical
advantages as compared to previous coordinate-based
methods, namely the use of standard statistical methods
(for example, weighting the calculations by both sample
size and study precision, use of effect sizes, inclusion
and assessment of residual heterogeneity, and so on).
In a meta-analysis of the BOLD response to emotional
facial stimuli [19], the sensitivity to detect real activations
(that is, the number of actually activated voxels appearing
as significant in the meta-analysis, divided by the total
number of actually activated voxels) was similar between
ES-SDM (55%) and SDM (51%) when only using peak
coordinates. However, the inclusion of the statistical
parametric maps led to a gradual and substantial increase
of the sensitivity of ES-SDM (73% when the statistical
parametric map of one study was included, 87% when
the statistical parametric maps of two studies were
included, 93% when the statistical parametric maps of
three studies were included, and so on). Therefore, given
the potential of this new method, we would encourage
authors to make their statistical parametric maps widely
available to the community on their laboratory websites
or via other means.
Online databases
In parallel with the development of new meta-analytical
methods, several freely-available website-based databases
of neuroimaging data have been made available. These
online databases may be classified in three groups, namely:
sets of original data (for example, the raw scanner images
from several samples of individuals); summary statistics
from the studies included in one meta-analysis (for exam-
ple, the mean ± standard deviation ROI volumes); and sets
of summary statistics of virtually all published studies.
T h eo n l i n es e t so fo r i g i n a ld a t aa r ec o m p o s e do ft h e
raw and/or pre-processed brain images, along with the
demographic and clinical characteristics of each of the
many anonymous participants. These databases may be
used by researchers to conduct their studies, thus being a
useful resource for highly accurate data analyses. It must
be noted, however, that analyses derived from these data-
sets should not be strictly considered meta-analyses, as
they do not necessarily exhaustively include all available
data. Examples of these datasets are BRAINNet (http://
www.brainnet.net), the fMRI Data Center (http://www.
fmridc.org) and OpenfMRI (http://www.openfmri.org).
Online databases containing the summary statistics
from the studies included in particular meta-analyses
represent a more interactive (and often complete) alter-
native to the traditional ‘supplementary materials’ that
accompany published meta-analyses. Importantly, these
online data may be used by other researchers to conduct
updated or secondary analyses. Examples of this type of
databases are the Bipolar Disorder Neuroimaging Data-
base (http://www.bipolardatabase.org) and the Major
Depressive Disorder Neuroimaging Database (http://
www.depressiondatabase.org) by Kempton and collea-
gues [41,42], as well as the series of peak-coordinate
databases from SDM meta-analyses (http://www.
sdmproject.com/database).
Finally, many sets of summary statistics of virtually all
published neuroimaging studies exist, allowing a rapid
retrieval of specific data in order to facilitate the meta-
analytic process. The developers of BrainMap (http://
www.brainmap.org), for instance, have been building and
updating an impressive database of neuroimaging find-
ings since 1987 [43]. Other available databases are the
AMAT toolbox (http://www.antoniahamilton.com/amat.
html), the Brede Database (http://neuro.imm.dtu.dk/ser-
vices/brededatabase) [44], the Internet Brain Volume
Database (http://www.cma.mgh.harvard.edu/ibvd) and
the Surface Management System Database (http://
sumsdb.wustl.edu/sums/index.jsp).
Another recent and promising online development
called NeuroSynth (http://www.neurosynth.org) [45]
deserves mentioning. NeuroSynth contains a set of sum-
mary statistics together with online functions aimed to
conduct real-time meta-analyses online. Unfortunately,
extraction of coordinates from publications is not manu-
ally verified, which may bias the results towards those
regions that the authors of the original articles wanted to
emphasize in the tables of the manuscripts. However,
when the researcher’s goal is to obtain a very fast and
preliminary meta-analysis of the literature, NeuroSynth
may be one of the first options.
Conclusions
In this paper we have reviewed the main types of meta-
analytic methods available for neuroimaging studies,
using examples from the mood and anxiety disorder lit-
erature to illustrate these methods.
ROI- and voxel-based methods each have advantages
and disadvantages, which are summarized in Table 2. Spe-
cifically, ROI-based meta-analyses use optimal statistical
methods, but they usually have a limited and likely biased
inclusion of studies [14]. Conversely, voxel-based meta-
analyses usually have a more exhaustive and unbiased
inclusion of studies, but their statistical methods are less
accurate. There are also relevant differences between the
different available voxel-based meta-analytic methods. For-
tunately, the field is rapidly evolving to develop more
accurate and robust methods.
Although voxel-based meta-analyses minimize the
effects of selectively reporting certain ROI, they are not
totally immune to publication biases, as negative results
may still be less likely to be published (what is known
as the file drawer problem). Authors of the original
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Page 8 of 11Table 2 Comparison of the main meta-analytic methods for neuroimaging studies comparing patients and controls
ROI-based meta-analyses Voxel-based meta-analyses
KDA/
old
ALE
Multilevel
KDA/new
ALE
SDM ES-SDM
Selection of studies
Exhaustive inclusion
of studies
Limited, as information for a given brain region is
present in few or no studies
Probable, as far as the included studies investigate the whole brain and not
only some ROIs (in which case should be discarded)
More probable, because statistical
parametric maps can also be
included
Unbiased inclusion
of studies
Limited, as information is only available for regions
hypothesized a priori, ignoring the rest of the brain
Probable, as far as the included studies do not use different statistical thresholds for different parts of the brain (this
is a strict inclusion criterion in SDM and ES-SDM)
Statistical analyses
Weighting of the
studies
Complete (sample size and study precision) None Partial (only sample size) Complete (sample size and study
precision)
Control of the
heterogeneity
Residual heterogeneity is correctly included in the
analyses
Residual heterogeneity
is not controlled, and
increases and
decreases are not
counteracted,
potentially leading to
voxels being detected
as increased and
decreased at the same
time
Residual heterogeneity is not included in the
weightings, but increases and decreases are
counteracted
Residual heterogeneity is correctly
included in the weightings
Study of the
heterogeneity
Possible, by means of meta-regressions and
subgroup analyses
Limited to subgroup
analyses
Possible, by means of meta-regressions and subgroup analyses
Correction for
multiple
comparisons
Possible Not possible, questionable or limited to conventional voxel-thresholded cluster-based methods
Description of the
effect sizes
Possible Not
possible
Possible though limited to pseudo-effect sizes based on the
proportion of studies reporting significant findings
Possible
Description of
relevant non-
significant trends
Possible, as the number of ROIs is manageable Not possible, or limited to the visual inspection of liberally thresholded maps, as the number of voxels ist o o
massive for a more accurate individual inspection
Please see text for further details. ALE: activation likelihood estimation; ES: effect size; KDA: kernel density analysis; ROI: region of interest; SDM: signed differential mapping.
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1papers are strongly encouraged to publish their results
even if they perceive them as being disappointing or
they do not find differences between patients and
controls.
Finally, we suggest that in any meta-analysis of neuroi-
maging data, independently of the chosen method, authors
should aim to: only include studies which explored the
whole brain; ensure that the same threshold throughout
the whole brain was used within each included study; and
explore the robustness of the findings with several com-
plementary analyses, for example, sensitivity analyses,
quantification of the ROI- or voxel-based between-study
heterogeneity [19], funnel plots of the values extracted
from the meta-analytic clusters or their peaks, and so on,
just like in any standard meta-analysis.
Author details
1Institute of Psychiatry, King’s College London, De Crespigny Park, London,
UK.
2Research Unit, FIDMAG-CIBERSAM, Sant Boi de Llobregat, Barcelona,
Spain.
Authors’ contributions
All authors drafted, read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 September 2011 Accepted: 8 March 2012
Published: 8 March 2012
References
1. Wager TD, Lindquist M, Kaplan L: Meta-analysis of functional
neuroimaging data: current and future directions. Soc Cogn Affect
Neurosci 2007, 2:150-158.
2. Lazar NA, Luna B, Sweeney JA, Eddy WF: Combining brains: a survey of
methods for statistical pooling of information. Neuroimage 2002,
16:538-550.
3. Radua J, Mataix-Cols D: Voxel-wise meta-analysis of grey matter changes
in obsessive-compulsive disorder. Br J Psychiatry 2009, 195:391-400.
4. Mulrow CD, Oxman AD: Cochrane Collaboration Handbook Oxford:
Cochrane Collaboration; 1996.
5. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7(3):177-188.
6. Viechtbauer W: Bias and efficiency of meta-analytic variance estimators
in the random-effects model. J Educ Behav Stat 2005, 30:261-293.
7. Fleiss JL, Gross AJ: Meta-analysis in epidemiology, with special reference
to studies of the association between exposure to environmental
tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991,
44:127-139.
8. Ades AE, Higgins JPT: The interpretation of random-effects meta-analysis
in decision models. Med Decis Making 2005, 25:646-654.
9. Elvik R: Evaluating the statistical conclusion validity of weighted mean
results in meta-analysis by analysing funnel graph diagrams. Accid Anal
Prev 1998, 30(2):255-266.
10. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis Orlando, FL:
Academic Press; 1985.
11. Cohen J: Statistical Power Analysis for the Behavioral Sciences Hillsdale, NJ:
Lawrence Erlbaum Associates; 1988.
12. Rotge JY, Guehl D, Dilharreguy B, Tignol J, Bioulac B, Allard M, Burbaud P,
Aouizerate B: Meta-analysis of brain volume changes in obsessive-
compulsive disorder. Biol Psychiatry 2009, 65(1):75-83.
13. Radua J, van den Heuvel OA, Surguladze S, Mataix-Cols D: Meta-analytical
comparison of voxel-based morphometry studies in obsessive-
compulsive disorder vs other anxiety disorders. Arch Gen Psychiatry 2010,
67(7):701-711.
14. Ioannidis JPA: Excess significance bias in the literature on brain volume
abnormalities. Arch Gen Psychiatry 2011, 68(8):773-780.
15. Uchida RR, Del-Ben CM, Araujo D, Busatto-Filho G, Duran FL, Crippa JA,
Graeff FG: Correlation between voxel based morphometry and manual
volumetry in magnetic resonance images of the human brain. An Acad
Bras Cienc 2008, 80(1):149-156.
16. Bergouignan L, Chupin M, Czechowska Y, Kinkingnehun S, Lemogne C, Le
Bastard G, Lepage M, Garnero L, Colliot O, Fossati P: Can voxel based
morphometry, manual segmentation and automated segmentation
equally detect hippocampal volume differences in acute depression?
Neuroimage 2009, 45(1):29-37.
17. Laird AR, McMillan KM, Lancaster JL, Kochunov P, Turkeltaub PE, Pardo JV,
Fox PT: A comparison of label-based review and ALE meta-analysis in
the Stroop task. Hum Brain Mapp 2005, 25(1):6-21.
18. Phan KL, Wager T, Taylor SF, Liberzon I: Functional neuroanatomy of
emotion: a meta-analysis of emotion activation studies in PET and fMRI.
Neuroimage 2002, 16(2):331-348.
19. Radua J, Mataix-Cols D, Phillips ML, El-Hage W, Kronhaus DM, Cardoner N,
Surguladze S: A new meta-analytic method for neuroimaging studies
that combines reported peak coordinates and statistical parametric
maps. Eur Psychiatry 2011.
20. Eickhoff SB, Bzdok D, Laird AR, Kurth F, Fox PT: Activation likelihood
estimation meta-analysis revisited. Neuroimage 2012, 59(32):2349-2361.
21. Wager TD, Phan KL, Liberzon I, Taylor SF: Valence, gender, and
lateralization of functional brain anatomy in emotion: a meta-analysis of
findings from neuroimaging. Neuroimage 2003, 19(3):513-531.
22. Turkeltaub PE, Eden GF, Jones KM, Zeffiro TA: Meta-analysis of the
functional neuroanatomy of single-word reading: method and
validation. Neuroimage 2002, 16(3 Pt 1):765-780.
23. Wager TD, Barrett LF, Bliss-Moreau E, Lindquist K, Duncan S, Kober H,
Joseph J, Davidson M, Mize J: The neuroimaging of emotion. In The
Handbook of Emotion. Edited by: Lewis M, Haviland-Jones JM, Barrett LF.
New York: Guilford Press; 2008:.
24. Costafreda SG, David AS, Brammer MJ: A parametric approach to voxel-
based meta-analysis. Neuroimage 2009, 46(1):115-122.
25. Ellison-Wright I, Ellison-Wright Z, Bullmore E: Structural brain change in
Attention Deficit Hyperactivity Disorder identified by meta-analysis. BMC
Psychiatry 2008, 8:51.
26. Eickhoff SB, Laird AR, Grefkes C, Wang LE, Zilles K, Fox PT: Coordinate-
based activation likelihood estimation meta-analysis of neuroimaging
data: a random-effects approach based on empirical estimates of spatial
uncertainty. Hum Brain Mapp 2009, 30(9):2907-2926.
27. Nakao T, Radua J, Rubia K, Mataix-Cols D: Gray matter volume
abnormalities in ADHD: voxel-based meta-analysis exploring the effects
of age and stimulant medication. Am J Psychiatry 2011, 168(11):1154-1163.
28. Via E, Radua J, Cardoner N, Happe F, Mataix-Cols D: Meta-analysis of gray
matter abnormalities in Autism Spectrum Disorder. Arch Gen Psychiatry
2011, 68:409-418.
29. Fusar-Poli P, Radua J, McGuire P, Borgwardt S: Neuroanatomical maps of
psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM
studies. Schizophr Bull 2011.
30. Palaniyappan L, Balain V, Radua J, Liddle PF: Structural correlates of
auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Res
2012.
31. Radua J, Mataix-Cols D: Heterogeneity of coordinate-based meta-analyses
of neuroimaging data: an example from studies in OCD-Authors’ reply.
Br J Psychiatry 2010, 197(1):77.
32. Radua J, Via E, Catani M, Mataix-Cols D: Voxel-based meta-analysis of
regional white matter volume differences in Autism Spectrum Disorder
vs. healthy controls. Psychol Med 2010, 41:1539-1550.
33. Bora E, Fornito A, Radua J, Walterfang M, Seal M, Wood SJ, Yucel M,
Velakoulis D, Pantelis C: Neuroanatomical abnormalities in schizophrenia:
a multimodal voxelwise meta-analysis and meta-regression analysis.
Schizophr Res 2011, 127(1-3):46-57.
34. Bora E, Fornito A, Yucel M, Pantelis C: Voxelwise meta-analysis of gray
matter abnormalities in bipolar disorder. Biol Psychiatry 2010,
67(11):1097-1105.
35. Bora E, Fornito A, Pantelis C, Yucel M: Gray matter abnormalities in Major
Depressive Disorder: a meta-analysis of voxel based morphometry
studies. J Affect Disord 2011.
Radua and Mataix-Cols Biology of Mood & Anxiety Disorders 2012, 2:6
http://www.biolmoodanxietydisord.com/content/2/1/6
Page 10 of 1136. Delvecchio G, Fossati P, Boyer P, Brambilla P, Falkai P, Gruber O, Hietala J,
Lawrie SM, Martinot JL, McIntosh AM, Meisenzahl E, Frangou S: Common
and distinct neural correlates of emotional processing in Bipolar
Disorder and Major Depressive Disorder: a voxel-based meta-analysis of
functional magnetic resonance imaging studies. Eur
Neuropsychopharmacol 2011, 22(2):100-113.
37. Etkin A, Wager TD: Functional neuroimaging of anxiety: a meta-analysis
of emotional processing in PTSD, social anxiety disorder, and specific
phobia. Am J Psychiatry 2007, 164(10):1476-1488.
38. Rotge JY, Guehl D, Dilharreguy B, Cuny E, Tignol J, Bioulac B, Allard M,
Burbaud P, Aouizerate B: Provocation of obsessive-compulsive symptoms:
a quantitative voxel-based meta-analysis of functional neuroimaging
studies. J Psychiatry Neurosci 2008, 33(5):405-412.
39. Neumann J, Fox PT, Turner R, Lohmann G: Learning partially directed
functional networks from meta-analysis imaging data. Neuroimage 2010,
49(2):1372-1384.
40. Laird AR, Eickhoff SB, Li K, Robin DA, Glahn DC, Fox PT: Investigating the
functional heterogeneity of the default mode network using coordinate-
based meta-analytic modeling. J Neurosci 2009, 29(46):14496-14505.
41. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM: Meta-analysis,
database, and meta-regression of 98 structural imaging studies in
bipolar disorder. Arch Gen Psychiatry 2008, 65(9):1017-1032.
42. Kempton MJ, Salvador Z, Munafo MR, Geddes JR, Simmons A, Frangou S,
Williams SC: Structural neuroimaging studies in major depressive
disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen
Psychiatry 2011, 68(7):675-690.
43. Laird AR, Lancaster JL, Fox PT: BrainMap: the social evolution of a
functional neuroimaging database. Neuroinformatics 2005, 3:65-78.
44. Nielsen FA, Hansen LK, Balslev D: Mining for associations between text
and brain activation in a functional neuroimaging database.
Neuroinformatics 2004, 2(4):369-380.
45. Yarkoni T, Poldrack RA, Nichols TE, Van Essen DC, Wager TD: Large-scale
automated synthesis of human functional neuroimaging data. Nat
Methods 2011, 8(8):665-670.
46. Carmona S, Bassas N, Rovira M, Gispert JD, Soliva JC, Prado M, Tomas J,
Bulbena A, Vilarroya O: Pediatric OCD structural brain deficits in conflict
monitoring circuits: a voxel-based morphometry study. Neurosci Lett
2007, 421(3):218-223.
47. van den Heuvel OA, Remijnse PL, Mataix-Cols D, Vrenken H,
Groenewegen HJ, Uylings HB, van Balkom AJ, Veltman DJ: The major
symptom dimensions of obsessive-compulsive disorder are mediated by
partially distinct neural systems. Brain 2009, 132(Pt 4):853-868.
48. Kim JJ, Lee MC, Kim J, Kim IY, Kim SI, Han MH, Chang KH, Kwon JS: Grey
matter abnormalities in obsessive-compulsive disorder: statistical
parametric mapping of segmented magnetic resonance images. Br J
Psychiatry 2001, 179:330-334.
49. Pujol J, Soriano-Mas C, Alonso P, Cardoner N, Menchon JM, Deus J,
Vallejo J: Mapping structural brain alterations in obsessive-compulsive
disorder. Arch Gen Psychiatry 2004, 61(7):720-730.
50. Szeszko PR, Christian C, Macmaster F, Lencz T, Mirza Y, Taormina SP,
Easter P, Rose M, Michalopoulou GA, Rosenberg DR: Gray matter structural
alterations in psychotropic drug-naive pediatric obsessive-compulsive
disorder: an optimized voxel-based morphometry study. Am J Psychiatry
2008, 165(10):1299-1307.
51. Valente AA Jr, Miguel EC, Castro CC, Amaro E Jr, Duran FL, Buchpiguel CA,
Chitnis X, McGuire PK, Busatto GF: Regional gray matter abnormalities in
obsessive-compulsive disorder: a voxel-based morphometry study. Biol
Psychiatry 2005, 58(6):479-487.
52. Yoo SY, Roh MS, Choi JS, Kang DH, Ha TH, Lee JM, Kim IY, Kim SI, Kwon JS:
Voxel-based morphometry study of gray matter abnormalities in
obsessive-compulsive disorder. J Korean Med Sci 2008, 23(1):24-30.
doi:10.1186/2045-5380-2-6
Cite this article as: Radua and Mataix-Cols: Meta-analytic methods for
neuroimaging data explained. Biology of Mood & Anxiety Disorders 2012
2:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Radua and Mataix-Cols Biology of Mood & Anxiety Disorders 2012, 2:6
http://www.biolmoodanxietydisord.com/content/2/1/6
Page 11 of 11